The scientific and anecdotal evidence surrounding the psychedelic substance Ibogaine continues to captivate both the medical community and those seeking alternatives for overcoming addiction. In an insightful conversation between Dr. Deborah Mash and Tom Feegel, CEO of Beond—an Ibogaine clinic in Cancun—critical themes emerge that highlight the potential of Ibogaine as a breakthrough in addiction therapy and cognitive enhancement.One key focus in Dr. Mash's conversation with Fegel is the importance of administering Ibogaine in medically superior facilities. Ibogaine, though potent in curbing opioid addiction and stimulating cognitive enhancement, poses risks, especially concerning cardiac health. While Ibogaine's reputation blossomed within the context of addiction recovery, the conversation pivots to explore its potential in treating a spectrum of other conditions, from PTSD to neurocognitive disorders.